Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Mar 15;7(4):1667-76.
eCollection 2014.

Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples

Veronica Bernard  1 , Niklas Gebauer  1 , Thomas Dinh  1 , Judith Stegemann  1 , Alfred C Feller  1 , Hartmut Merz  1
Affiliations
Comparative Study

Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples

Veronica Bernard et al. Int J Clin Exp Pathol. .

Abstract

Decalcified formalin-fixed and paraffin-embedded (dFFPE) bone marrow trephines remain the primary source of gDNA in hematopathological diagnostics. Here, we investigated the applicability of next-generation sequencing (NGS) to dFFPE samples. Chronic myelomonocytic leukaemia (CMML) is a haematopoietic stem cell malignancy delineated by genetic heterogeneity. Recently characteristic mutations have been identified for this entity in a distinct group of genes (TET2, CBL, KRAS). We comparatively investigated DNA extracted from fresh mononuclear cells as well as dFFPE samples from four CMML patients employing a commercially available primer set covering the above mentioned and well characterized mutational hotspots in CMML followed by an amplicon based next-generation deep-sequencing (NGS) approach. As we observed high quality run data as well as complete concordance between both sample types in all cases, we further validated the potential of NGS in hematopathology on a larger cohort of CMML patients (n=39), detecting sequence variations in 84.6% of patients. Sequence analysis revealed 92 variants, including five known polymorphisms, ten silent mutations, 36 missense mutations, 14 nonsense mutations, 24 frame shift mutations and three potential splice site mutations. Our findings ultimately demonstrate the applicability of NGS to dFFPE biopsy specimen in CMML and thus allowing the pathologist to evaluate prognostically relevant mutations at a high resolution and further contribute to risk stratification for the individual patient.

Keywords: Next-generation sequencing; chronic myelomonocytic leukaemia; decalcified; formalin-fixed; paraffin-embedded samples.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Combined coverage data of TET2, CBL and KRAS next-generation sequencing on dFFPE samples. Combined, forward and reverse reads for CBL and KRAS (A), overall forward and reverse TET2 reads per amplicon (B) and combined TET2 reads for all amplicons (C). Data reveal a consistent as well as high resolution coverage and summarized forward/reverse strand sequencing of TET2 illustrate a slight predominance of the A-sequencing-bead prepared forward strand.
Figure 2
Figure 2
TET2 Mutation types and distribution in CMML samples. Nine missense mutations within the two evolutionarily conserved regions (black boxes), 14 nonsense mutations (red boxes), 23 frameshift mutations (blue ovals) and three potential splice site mutations (orange ovals) in 27 of 39 patients (69.2%) at an average of 1.38 mutations per patient. Four of these mutations could be detected independently in multiple patients.
See this image and copyright information in PMC

References

    1. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O’Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–2405. - PMC - PubMed
    1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant’Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390. - PubMed
    1. Swerdlow SH. WHO. 2008. WHO Classification of Tumors of Haematopoetic and Lymphoid Tissues.
    1. Anon C. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet. 1991;55:57–65. - PubMed
    1. Cortes J. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep. 2003;2:202–208. - PubMed

Publication types

MeSH terms